Navigation Links
PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
Date:9/9/2009

PRINCETON, N.J., Sept. 9 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that it has completely paid down its Convertible Senior Notes that were due 2024 and obtained a credit line that can be used for general corporate purposes.

"The combination of our financial restructuring, business process improvements and solid operating performance has resulted in a healthy backlog of new business and renewed optimism," commented Jeffrey P. McMullen, president and chief executive officer. "With our financial challenges behind us, clients can be assured PharmaNet Development Group is in a strong position for long term growth."

In addition, the Company has continued to expand its global reach in the Asia Pacific region. The recently opened office in Manila, Philippines further enhances PharmaNet Development Group's presence in the region consisting of two offices in India, two offices in China, offices in South Korea, Singapore and Taiwan, and field based staff in Australia, Malaysia and Thailand. The Company is planning an expansion of its Singapore office in 2010 and continues to invest in personnel and other strategic assets.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 40 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.

    Contact: Anne-Marie Hess
    Phone: (609) 951-6842
    E-mail: ahess@pharmanet.com


'/>"/>
SOURCE PharmaNet Development Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
2. PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
3. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
4. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
5. PharmaNet Development Group Agrees to be Acquired by JLL Partners
6. China Biologic Products Appoints Director of Research and Development
7. Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting
8. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
9. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
10. ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development
11. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 27, 2016 , ... Rolf K. Hoffmann, former senior vice ... University of North Carolina Kenan-Flagler Business School effective June 27. , ... with a focus on the school’s international efforts, leading classes and participating in ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):